. 2020 Dec 16;31(23-24):1237–1259. doi: 10.1089/hum.2020.116

Table 2.

I-124 percentage organ biodistribution following administration of I-124-labeled vectors

NHP No.^a	Route	Vector Immune Status ^a	AAV Serotype/Transgene^a	Liver	Heart	Vertebrae	Spleen	CSF/Brain	Body ^b
1	Intravenous	Naive	10/mCherry	18.4	11.2	4.2	1.3	0.3	64.6
1	Intravenous	Immune	10/FXN	31.5	3.1	5.8	6.1	0.2	53.2
2	Intravenous	Naive	9/mCherry	41.3	5.2	6.3	1.9	0.1	45.1
2	Intravenous	Immune	9/FXN	45.4	3.3	4.1	8.6	0.1	38.4
3	Intracisternal	Naive	10/mCherry	12.0	5.0	1.0	0.5	14.0	67.6
3	Intracisternal	Immune	10/FXN	11.4	2.1	1.8	7.2	14.5	63.0
4	Intracisternal	Naive	9/mCherry	9.4	9.5	0.2	0.5	12.6	67.8
4	Intracisternal	Immune	9/FXN	26.6	3.2	2.1	6.4	21.5	40.2
5	Intracisternal	Naive	9/mCherry	20.2	5.0	2.6	1.8	4.0	66.4
6	Intracisternal	NaI control	I-124 alone	2.4	1.5	0.4	0.1	0.1	95.4
6	Intravenous	NaI control	I-124 alone	6.3	4.5	0.6	0.5	0.1	87.9

The percentage distribution for each organ is equal to 100^*a_oi where the distribution fractions a_oi were calculated from Equation (1).

^{^a}

See Table 1 for description of NHP, immune status, and description of the AAV vectors.

^{^b}

Body activity represents all I-124 activity that was not assigned to the five organs listed or the thyroid.

CSF, cerebral spinal fluid.